News Releases

News Releases

Jul 01, 2019
NEW YORK --(BUSINESS WIRE)--Jul. 1, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it joined the broad-market Russell 3000 ® Index at the conclusion of the 2019 Russell indexes
May 30, 2019
NEW YORK --(BUSINESS WIRE)--May 30, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), today announced that management will present at three investor conferences in June: Jefferies 2019 Global Healthcare Conference Tuesday, June 4th 9:00AM Eastern Time New York, NY Goldman Sachs 40 th Annual Global
Apr 23, 2019
Focused Agreement is on Therapeutic Area of Mutual Interest NEW YORK --(BUSINESS WIRE)--Apr. 23, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of uro-oncology, today announced that it has entered into an
Mar 05, 2019
NEW YORK --(BUSINESS WIRE)--Mar. 5, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), today announced that management will present at two investor conferences in March: Cowen and Company 39 th Annual Health Care Conference Tuesday, March 12 th 11:20AM Eastern Time Boston, MA Oppenheimer 29 th Annual